Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference
Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference
Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Canaccord Genuity 42nd Annual Growth Conference, which will take place in Boston, Massachusetts, from August 8 to 11, 2022.
Olivier Taelman, Nyxoah’s Chief Executive Officer, is scheduled to present a corporate update on Wednesday, August 10, 2022, at 3:30pm EDT. A webcast of the presentation will be available on the of Nyxoah’s Investor Relations website. The Company will also be available for 1x1 meetings with institutional investors attending the event.
Nyxoah’s updated Investor Presentation can be accessed on the section of the Company’s Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit .
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
0
Jeremy Feffer, VP IR and Corporate Communications
Attachment
